Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherAbout the NetworkJoin the NetworkProductsSub-MenuProducts OverviewBlog ProBlog PlusBlog PremierMicrositeSyndication PortalsAbout UsContactSubscribeSupport
Book a Demo
Search
Close

Recent PTAB Developments for Regeneron’s Aflibercept Formulation Patent

June 20, 2025

Updates on Aflibercept Biosimilar Approvals and BPCIA Litigation

June 8, 2024

Federal Circuit Dismisses Appeals in Regeneron v. Mylan (Aflibercept) BPCIA Litigation

April 22, 2024

DOJ Files False Claims Act Complaint Against Regeneron, Alleging Fraudulent Eylea Drug Pricing

April 22, 2024

Post-Trial Updates on Regeneron v. Mylan (Aflibercept) BPCIA Litigation

March 1, 2024

Celltrion and Samsung File IPR Petitions on Aflibercept Patents

February 27, 2023

Celltrion Files IPR Petition on Aflibercept Patent

January 27, 2023

Outlook Therapeutics Re-Submits Its Ophthalmic Bevacizumab BLA

September 3, 2022

Amgen Announces Positive Top-Line Results from Phase 3 Study of Eculizumab Biosimilar

September 1, 2022

Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for Ustekinumab Biosimilar

May 18, 2022

Post navigation

Older Posts 
Subscribe: Subscribe via RSS
Blogs
  • Big Molecule Watch
Firm/Org
  • Goodwin Procter

Grace Truong

Subscribe: Subscribe via RSS
Blogs
  • Big Molecule Watch
Firm/Org
  • Goodwin Procter
Have questions? Call 1-800-913-0988 or email sales@lexblog.com.
Facebook LinkedIn Twitter RSS
  • About LexBlog
  • Our Beliefs
  • Our Team
  • Careers
  • Press
  • Contact LexBlog
  • Privacy Policy
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • RSS Terms of Service
  • Syndication Terms of Service
  • Blog Pro
  • Blog Plus
  • Blog Premier
  • Microsite
  • Syndication Portals
  • LexBlog Community
  • Submit a Request
  • Support Center
  • System Status
  • Resource Center
  • Blogging 101
Copyright © 2025, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo